Trial Profile
An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 1 to 17 Years
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- Sponsors Cumberland Pharmaceuticals; Innoviva; Theravance Biopharma
- 10 Oct 2023 According to a Cumberland Pharmaceuticals media release, the results from this trial were published in the Antimicrobial Agents and Chemotherapy Journal.
- 10 Oct 2023 Results presented in the Cumberland Pharmaceuticals Media Release.
- 01 Feb 2022 Status changed from recruiting to discontinued.